Q2 Expectations The Research and Development segment's revenues are expected to be $2.1 billion, implying a 1.7% rise from the year-ago reported figure.The top 10 pharmaceutical companies chose IQVIA to support the novel respiratory vaccine development, which could lead to a breakthrough as the vaccine targets several respiratory viruses simultaneously. Such a feat is anticipated to have benefited this segment's revenues.Our estimate for Contract sales and Medical solutions' revenues is pegged at $177 milli ...

IQV has reported impressive first-quarter 2024 results. Adjusted earnings (excluding 98 cents from nonrecurring items) were $2.5 per share, which beat the Zacks Consensus Estimate by 2.8% and increased 3.7% from the year-ago reported figure. Total revenues of $3.7 billion surpassed the consensus estimate by 1.2% and grew 2.3% from the year-ago quarter. The company's addressable market size is more than $330 billion. It consists of outsourced research and development, real-world evidence and connected health ...

IQVIA Holdings Inc. (IQV) yesterday unveiled a clinical trial technology platform, One Home for Sites. The platform streamlines the process of management of trials by acting as a single sign-on and a single dashboard for various systems and tasks. By integrating various clinical applications into a single platform, One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management. This consolidation tackles the issue of technology overload, where sta ...

Last time, I commented on the company's strengths in unlocking risk capital for shareholders, namely via 1) exceptional net operating profit after tax relative to the capital invested to produce these numbers, 2) decompression of post-tax margins with increasing capital turnover, and 3) the company's propensity to throw off stable, high amounts of free cash flow to its owners. Figure 1. IQV price evolution, 12 months Seeking Alpha You can check out a deeper analysis on what the company does, its business li ...

Shares of IQVIA Holdings Inc. (IQV) have risen 15% over the past year, outperforming the 12.1% growth of the industry it belongs to. The company has an expected long-term (three to five years) EPS growth rate of 10.9%. Its earnings for 2024 and 2025 are anticipated to grow 8.4% and 12.5%, respectively, year over year. Factors That Bode Well IQV's extensive data collection, comprising more than one billion patient records and 61 petabytes of proprietary data from 150,000 suppliers, sets it apart and creates ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 ______ ...

IQVIA Holdings Analytics Inc. (IQV) has reported impressive first-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings (excluding 98 cents from non-recurring items) were $2.5 per share, beating the Zacks Consensus Estimate by 2.8% and increasing 3.7% from the year-ago reported figure. Total revenues of $3.7 billion surpassed the consensus estimate by 1.2% and grew 2.3% from the year-ago quarter.The IQV stock has gained 25.5% over the past year, outperformin ...

100% 50% 75% 25% 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q1 2024 earnings call In all cases where historical results are presented or past performance is described, we note that past performance is not a reliable indicator of future results and performance. Legal IQVIA Template (V2.1.0) 1 st Quarter Balance Sheet and Cash Flow Items and Metrics Dollars are at actual foreign exchange rates. (1) Calculated using last twelve months Adjusted EBITDA. (2) See reconciliation ...

IQVIA Holdings Inc. (NYSE:IQV) Q1 2024 Earnings Conference Call May 2, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations and Treasury Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Conference Call Participants Shlomo Rosenbaum - Stifel Max Smock - William Blair Anne Samuel - JP Morgan David Windley - Jefferies Jailendra Singh - Truist Securities Ann Hynes - Mizuho Securities John Kim - Bank o ...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.83%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.82 per share when it actually produced earnings of $2.84, delivering a surprise of 0.71%.Over the last four quarters, ...